Michael Charlton to Disease Progression
This is a "connection" page, showing publications Michael Charlton has written about Disease Progression.
Connection Strength
0.739
-
A longitudinal study of whole body, tissue, and cellular physiology in a mouse model of fibrosing NASH with high fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2017 Jun 01; 312(6):G666-G680.
Score: 0.106
-
Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence. Liver Int. 2015 Nov; 35(11):2433-41.
Score: 0.095
-
Ledipasvir and Sofosbuvir Plus Ribavirin for Treatment of HCV Infection in Patients With Advanced Liver Disease. Gastroenterology. 2015 Sep; 149(3):649-59.
Score: 0.094
-
Fast food diet mouse: novel small animal model of NASH with ballooning, progressive fibrosis, and high physiological fidelity to the human condition. Am J Physiol Gastrointest Liver Physiol. 2011 Nov; 301(5):G825-34.
Score: 0.072
-
Insulin resistance, serum adipokines and risk of fibrosis progression in patients transplanted for hepatitis C. Am J Transplant. 2009 Jun; 9(6):1406-13.
Score: 0.062
-
Approach to recurrent hepatitis C following liver transplantation. Curr Gastroenterol Rep. 2007 Mar; 9(1):23-30.
Score: 0.053
-
Noninvasive indices of fibrosis in NAFLD: starting to think about a three-hit (at least) phenomenon. Am J Gastroenterol. 2007 Feb; 102(2):409-11.
Score: 0.053
-
Impact of obesity on treatment of chronic hepatitis C. Hepatology. 2006 Jun; 43(6):1177-86.
Score: 0.051
-
Natural history and management of hepatitis C infection after liver transplantation. Semin Liver Dis. 2004; 24 Suppl 2:79-88.
Score: 0.043
-
Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease. Liver Transpl. 2001 Jul; 7(7):608-14.
Score: 0.036
-
Early identification of recipients with progressive histologic recurrence of hepatitis C after liver transplantation. Hepatology. 2000 Nov; 32(5):1125-30.
Score: 0.034
-
Longitudinal correlations between MRE, MRI-PDFF, and liver histology in patients with non-alcoholic steatohepatitis: Analysis of data from a phase II trial of selonsertib. J Hepatol. 2019 01; 70(1):133-141.
Score: 0.030
-
Treatment of carcinoma in situ with intravesical bacillus Calmette-Guerin without maintenance. J Urol. 2002 Jun; 167(6):2408-12.
Score: 0.010